Heating Things Up…While Keeping Our Cool!
Heating Things Up…While Keeping Our Cool!
 Heating Things Up…While Keeping Our Cool!
STM Newsletter
April 2021
Updates
Nominations
Calling all members: Help shape the future of the Society for Thermal Medicine!!!
It is the time of year for members to help update the STM leadership.  A call for nominations will be sent to members soon. Please considering nominating yourself or your colleagues to serve the Society through participating in STM council activities. 
STM is seeking:
- Vice-President with expertise in the Clinical track
- Secretary/ Treasurer in-Training 

- Councilors (2 each) from the clinical, biological and physics/ engineering track
Virtual Symposia
One of the best ways that STM members can come together is to renew their membership and participate in Thermal Medicine based virtual events, which will be interactive in real-time so STM members can engage with the speakers and foster good dialogue.

Upcoming virtual events include:
May 15-16th (On Demand Sessions):
STM and ASLMS will partner for the second joint symposium.  The topic for this event is Photothermal Nanoparticles.  This content is free for STM members.
Register HERE.
Speakers:
Robert Griffin, PhD:
Professor, Radiation Oncology, University of Arkansas for Medical Sciences:
Gold photothermal nanoparticles for cancer and bacteria
Kaushal Rege, PhD:
Professor, Chemical Engineering, Arizona State University:
Gold nanoparticles for wound sealing
Nicole Levi, PhD:
Associate Professor, Plastic and Reconstructive Surgery, Wake Forest University School of Medicine:
Photothermal polymer nanoparticles
Rohan Fernandes, PhD:
Associate Professor, Department of Medicine, George Washington School of Medicine and Health Sciences:
Prussian blue nanoparticles and immuneresponses
Kanav Khosla, PhD:
Post-doctoral Research Associate, Mechanical Engineering, University of Minnesota:
Using photothermal nanoparticles for warming cryopreserved tissues
Ravi Singh, PhD:
Associate Professor, Cancer Biology, Wake Forest University School of Medicine:
Photothermalsensitization of breast cancer to radiation 
May 13, 11am-1pm EDT (10-12 CDT, 8-10 PDT): The Society for Thermal Medicine is pleased to announce complimentary registration is now open for our special virtual symposium on “Therapeutic Ultrasound in Oncology”.
Sponsored by the Focused Ultrasound Foundation, this therapeutic ultrasound symposia will be held May 13 between 10am-12pm CDT (8am-10am PDT, 11am-1pm EDT). The emphasis of the symposia is to cover preclinical and clinical advances in FUS oncological therapies that will be of interest to the Society for Thermal Medicine, as well as members of ISTU and general FUS communities. 
This event will consist of five talks followed by a live Q&A panel discussion at the end of the symposium.
Register HERE. The last day to register is May 10, 2021.
Symposium Chairs: 
Dr. Chris Diederich, PhD
Professor, Radiation Oncology, UCSF Comprehensive Cancer Center
Dr. Allison Payne, PhD
Associate Professor, Dept. of Radiology and Imaging Sciences, University of Utah

Talk #1: Samuel Pichardo, PhD, (MR Guided FUS Program Co-Lead: Technical Assistant Professor, Radiology and Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine,
University of Calgary): MRg FUS hyperthermia for pelvic and head/ neck cancers

Talk #2: Constantin C. Coussios, PhD, FREng (Director, Institute of Biomedical Engineering, University of Oxford), Dr. Paul Lyon, MD, PhD (Specialist Registrar in Interventional Radiology, Department of Radiology, Oxford University Hospitals NHS Trust), and Dr. Michael D. Gray, PhD (Senior Research Fellow in Clinical Therapeutic Ultrasound, University of Oxford) - Thermally-triggered release without thermometry? Results from a first-in-human trial of ultrasound-guided ultrasound-triggered targeted delivery from thermosensitive liposomes in patients with liver tumours
Talk #3: Dr. Gregory J. Czarnota, PhD, MD, FRCPC, MRMD (MRSC) (Chief, Department of Radiation Oncology, Head, Radiation Treatment Program, Radiation Oncologist and Clinician Scientist, Department of Radiation Oncology, and Physical Sciences Platform, Sunnybrook Health Sciences Centre, and Sunnybrook Research Institute Professor, Departments of Radiation Oncology and Medical Biophysics, University of Toronto ) - Ultrasound-Stimulated Microbubbles and Radiotherapy - Preclinical Investigations and Translation to a Clinical Trial

Talk #4: Dr. Pejman Ghanouni, MD, PhD (Associate Professor of Radiology, and, by courtesy, of Gynecology, Neurosurgery, and Urology, Director, Minimally Invasive MR Interventional Center, Director, Stanford FUS Center of Excellence): MRg FUS Ablative Therapies in Oncology 

Talk #5: Dr. Suzanne LeBlang, MD (Director of Clinical Relationships Focused Ultrasound Foundation): Current Status and Future Directions of Focused Ultrasound in Oncology  









Thank you to our sponsor, the Focused Ultrasound Foundation!
July 21, 2021: STM will partner with the Society for Neuro-Oncology for a joint session on thermal therapies for brain tumors entitled “Laser Hyperthermia for CNS Disorders”. More details will be provided soon!
October 6-9, 2021: The 13th International Congress of Hyperthermic Oncology will be held in Rotterdam, The Netherlands.
ICHO occurs every four years and combines expertise from three partnering societies:  the Asian Society of Hyperthermic Oncology (ASHO), the Society for Thermal Medicine (STM), and the European Society for Hyperthermic Oncology (ESHO).
The deadline for abstract submission is April 30, 2021
Topics include:
•Clinical hyperthermia trials
•Cryotherapy
•Emerging hyperthermia biology
•Experimental hyperthermia studies
•High intensity focused ultrasound hyperthermia technology
•HIPEC and HIVEC
•Hyperthermia in pediatrics
•Image guidance
•Mild hyperthermia
•Modeling, treatment planning and optimization
•MR imaging & thermometry
•Nanoparticles hyperthermia & ablation techniques
•Nanotechnology and drug delivery
•Novel targeted drug delivery approaches
•Radiation/Chemo + hyperthermia
•Radiofrequency and microwave electromagnetic hyperthermia technology
•Temperature monitoring
•Thermal ablation biology
•Thermal ablation devices (RF, MW, Laser)
•Thermal dose and treatment outcome
•Thermal therapies    
•Vendor presentations
•other topics
Updates: The Minorities and Women in Science Committees Mentorship Program
The mentorship program has been underway for the past two months and mentees are thriving:
“The best aspect of  being a mentee is rediscovering my own inner skills and realization that we all have it in ourselves, just need to have the self-realization and sometimes when we talk with experienced mentors, we kind of re discover our own self better.” - Krishna Ramajayan
Junior scientists: Do you want to learn more about how to advance your careers in academia or industry?  Having a mentor can help you find your path! Join senior STM members virtually for 1 on 1 monthly mentoring.
The initiative is open to ALL members of the Society regardless of background; however, the Committees strongly encourage female and minority members to take part.
Senior members interested in serving as mentors should contact Rajiv Chopra (rajiv.chopra@utsouthwestern.edu)
Junior members interested in receiving mentorship should contact Anjan Motamarry (amotamarry@mgh.harvard.edu
Membership - Support STM during this critical time
Don’t let your STM membership lapse! Even though we are not having an in-person meeting until ICHO later this year, STM is planning webinars to spread our knowledge, develop new ideas, and engage with one another.  Now is a critical time to show your support for STM and rebuild your connections. 
Renew your membership here for 2021: https://www.thermaltherapy.org/ebusSFTM/MEMBERSHIP.aspx
Membership in The Society for Thermal Medicine is open to anyone interested in the study of thermal medicine.
Membership rights and privileges include:
  • Participating in society elections
  • Committee service
  • Access to restricted “members-only” areas of the STM website
  • Discount on ICHO 2021 registration fees
  • Free registration to all STM webinars/mini-symposia
  • A 30% discount on IJH article submission fees
  • Complementary sponsorship of 2 junior investigators 
Connect with us!
If you have suggestions for how we can better improve STM as we delve together into these new plans, please reach out, and let us know:
Job Hunters
STM has a new member's only jobs section on our website, for both industry and academic positions. NEW Jobs have recently been posted! Please note, in order to access the jobs page you must be signed in as an active STM member. Send any jobs wanted or job postings to stm@allenpress.com and we will add them to the website.  Please contact us if you have any questions/concerns.
International Journal of Hyperthermia Updates
Do you like learning more about Thermal Medicine? Remember that STM is the official sponsor for the International Journal of Hyperthermia.

STM members receive a valuable 30% discount on publishing charges.  Now is a great time to work from home and write your manuscripts for submission to IJH!  IJH is on track to receive a record number of submissions this year and its impact factor continues to increase annually (3.589 for 2018).  
IJH is always interested in innovative ideas to increase the breadth of the journal and we strongly hope that the special issues venue will help in the expansion. We are open to additional Industry-Sponsored or Foundation sponsored Special Issues. Please let us know if you have an idea for one!
Featured International Journal of Hyperthermia Articles
Raniv D. Rojo, Joy Vanessa D. Perez, Jossana A. Damasco, Guoyu Yu, Song-Chang Lin, Francisco M. Heralde III, Nora M. Novone, Elmer B. Santos, Sue-Hwa Lin & Marites P. Melancon
Published online: 22 Apr 2021
Views: 113
Abstract
Background
Metastatic prostate cancer in bone is difficult to treat as the tumor cells are relatively resistant to hormonal or chemotherapies when compared to primary prostate cancer. Irreversible electroporation (IRE) is a minimally invasive ablation procedure that has potential applications in the management of prostate cancer in bone. However, a common limitation of IRE is tumor recurrence, which arises from incomplete ablation that allows remaining cancer cells to proliferate. In this study, we combined IRE with radium-223 (Ra-223), a bone-seeking radionuclide that emits short track length alpha particles and thus is associated with reduced damage to the bone marrow and evaluated the impact of the combination treatment on bone-forming prostate cancer tumors.
Methods
The antitumor activity of IRE and Ra-223 as single agents and in combination was tested in vitro against three bone morphogenetic protein 4 (BMP4)-expressing prostate cancer cell lines (C4-2B–BMP4, Myc-CaP–BMP4, and TRAMP-C2–BMP4). Similar evaluation was performed in vivo using a bone-forming C4-2B–BMP4 tumor model in nude mice.
Results
IRE and Ra-223 as monotherapy inhibited prostate cancer cell proliferation in vitro, and their combination resulted in significant reduction in cell viability compared to monotherapy. In vivo evaluation revealed that IRE with single-dose administration of Ra-233, compared to IRE alone, reduced the rate of tumor recurrence by 40% following initial apparent complete ablation and decreased the rate of proliferation of incompletely ablated tumor as quantified in Ki-67 staining (53.58 ± 16.0% for IRE vs. 20.12 ± 1.63%; for IRE plus Ra-223; p = 0.004). Histological analysis qualitatively showed the enhanced killing of tumor cells adjacent to bone by Ra-223 compared to those treated with IRE alone.
Conclusion
IRE in combination with Ra-223, which enhanced the destruction of cancer cells that are adjacent to bone, resulted in reduction of tumor recurrence through improved clearance of proliferative cells in the tumor region.
Sri Kamal Kandala, Anirudh Sharma, Sahar Mirpour, Eleni Liapi, Robert Ivkov & Anilchandra Attaluri
Published online: 14 Apr 2021
Views: 142
Abstract
Purpose
Alternating magnetic field (AMF) tissue interaction models are generally not validated. Our aim was to develop and validate a coupled electromagnetic and thermal model for estimating temperatures in large organs during magnetic nanoparticle hyperthermia (MNH).
Materials and methods
Coupled finite element electromagnetic and thermal model validation was performed by comparing the results to experimental data obtained from temperatures measured in homogeneous agar gel phantoms exposed to an AMF at fixed frequency (155 ± 10 kHz). The validated model was applied to a three-dimensional (3D) rabbit liver built from computed tomography (CT) images to investigate the contribution of nanoparticle heating and nonspecific eddy current heating as a function of AMF amplitude.
Results
Computed temperatures from the model were in excellent agreement with temperatures calculated using the analytical method (error < 1%) and temperatures measured in phantoms (maximum absolute error <2% at each probe location). The 3D rabbit liver model for a fixed concentration of 5 mg Fe/cm3 of tumor revealed a maximum temperature ∼44 °C in tumor and ∼40 °C in liver at AMF amplitude of ∼12 kA/m (peak).
Conclusion
A validated coupled electromagnetic and thermal model was developed to estimate temperatures due to eddy current heating in homogeneous tissue phantoms. The validated model was successfully used to analyze temperature distribution in complex rabbit liver tumor geometry during MNH. In future, model validation should be extended to heterogeneous tissue phantoms, and include heat sink effects from major blood vessels.


Georgios Imseeh, Sharon L. Giles, Alexandra Taylor, Matthew R. D. Brown, Ian Rivens, Richard Gordon-Williams, Gail ter Haar & Nandita M. deSouza
Published online:  22 Apr 2021 
Views: 64
Abstract
Objective
To document longitudinal symptom, quality-of-life and imaging response in patients with recurrent gynecological tumors treated with magnetic resonance guided high intensity focused ultrasound (MRgHIFU), and compare changes in patients with intra- versus extra-pelvic lesions.
Methods
Eleven symptomatic patients with painful recurrent gynecological tumors were treated with MRgHIFU (Profound Sonalleve) in a prospective single center study (NCT02714621). Pain scores, analgesic intake and quality-of-life metrics, whole tumor volume, and perfused tumor volume from Gadolinium-enhanced T1W imaging documented before and up to 90 days after treatment were compared between patients with intra- and extra-pelvic tumors.
Results
Two of five patients with intra-pelvic and three of six patients with extra-pelvic tumors were classified as responders (>2 point reduction in NRS pain score without analgesia increase or a > 25% reduction in analgesic use). Cohort reductions in worst pain scores were not significant for either group. Emotional functioning for the whole cohort improved, although physical functioning did not. Ablative thermal temperatures were achieved in three patients with extra-pelvic tumors, but in none whose tumors were intra-pelvic. Pain response did not correlate with thermal dose. Tumor volume increased by 18% immediately post-treatment in the extra-pelvic but not in the intra-pelvic group. Ratio of perfused to whole lesion volume decreased by >20% by day 30 in extra-pelvic, but not intra-pelvic tumors although at day 30 both extra-pelvic and intra-pelvic tumors increased in volume.
Conclusion
MRgHIFU treatments can be delivered safely to patients with recurrent gynecological tumors. Extra-pelvic tumors responded better than intra-pelvic tumors and showed immediate swelling and reduction in perfused volume by day 30. 
Twitter Facebook Instagram LinkedIn
STM Business Office | PO Box 7065 | Lawrence, KS 66044-1897 USA
powered by emma